fax: (0049) 3419712339
Version of Record online: 18 APR 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 55, Issue 6, pages 1700–1710, June 2012
How to Cite
Fischer, J., Böhm, S., Scholz, M., Müller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D. R., Stewart, G. J., van Bömmel, F., Brodzinski, A., Fülöp, B., Migaud, P. and Berg, T. (2012), Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55: 1700–1710. doi: 10.1002/hep.25582
Potential conflict of interest: Nothing to report.
This work was supported by the German Competence Network for Viral Hepatitis (Hep-Net), funded by the German Ministry of Education and Research (BMBF, grant no. 01 KI 0437, project no. 10.1.3, and core project no. 10.1 Genetic host factors in viral hepatitis and Genetic Epidemiology Group in viral hepatitis), by the EU-Vigilance Network of Excellence Combating Viral Resistance (VIRGIL, project no. LSHM-CT-2004-503359), and by the BMBF Project: Host and viral determinants for susceptibility and resistance to hepatitis C virus infection (grant no. 01KI0787). Parts of the work were supported by an Australian Research Council Linkage Project Grant (LPO0990067), a National Health and Medical Research Council Grant (1006759), and the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney. M.S. was funded by the Leipzig Interdisciplinary Research Cluster of Genetic Factors, Clinical Phenotypes and Environment (LIFE Center, Universität Leipzig). LIFE is funded by means of the European Union, by the European Regional Development Fund, and by means of the Free State of Saxony within the framework of the excellence initiative.
- Issue online: 29 MAY 2012
- Version of Record online: 18 APR 2012
- Accepted manuscript online: 11 JAN 2012 04:52AM EST
- Manuscript Accepted: 21 DEC 2011
- Manuscript Received: 3 AUG 2011
- 1World Health Organization. Hepatitis C. Global alert and response. 2002. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html. Accessed on 1 August 2011.
- 22Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics 2006; 131: 1887-1898., , , , .
- 47Efficacy and safety of TMC435 in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR study. Hepatology 2010; 52: 57., , , , , , et al.
- 48IL28B SNP geographical distribution and antiviral responses in a 28-day phase 2a trial of PSI-7977 daily dosing plus peg-IFN/RBV. Hepatology 2010; 52: 711., , , , , , et al.
- 49IL28B polymorphisms and kinetics of antiviral activity for ANA598 in combination with pegylated interferon-alfa2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. Hepatology 2010; 52: 1200., , , , , , et al.